Harrow (FRA:3IP) Moat Score: 3/10 (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3IP Harrow Inc FRA:3IP
76 GF Score
Price €33.00
GF Value €33.34
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Harrow Moat Score?

Harrow FRA:3IP -0.60% 76 Moat Score is 3 as of Aug. 20, 2026. GuruFocus rates FRA:3IP with a GF Score™ of 76/100 and a GF Value™ of €33.34 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,025 Drug Manufacturers companies, Harrow ranks better than 86.05% on this metric.

Harrow has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Harrow has No Moat: Harrow Inc has very weak competitive advantages, with limited market leadership and low customer switching costs. The company operates in a highly competitive pharmaceutical market with minimal regulatory barriers or proprietary technology.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Harrow might have No Moat - Very weak/transient advantages.

Harrow  (FRA:3IP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Harrow Moat Score Related Terms

FRA:3IP vs XERS, PRGO, PAHC: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harrow Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harrow's Moat Score distribution charts can be found below:

* The bar in red indicates where Harrow's Moat Score falls into.


FRA:3IP
76GF Score
Harrow Inc FRA:3IP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Harrow (FRA:3IP) has a Moat Score of 3 as of Aug. 20, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Harrow ranks #143 out of 1025 companies in the Drug Manufacturers industry, placing it in the top 14%.
Is Harrow's Moat Score too high?
Harrow's current Moat Score is 3. Based on the distribution chart, Harrow ranks #143 out of 1025 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Harrow has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harrow's Moat Score compare to XERS and PRGO?
According to the Drug Manufacturers industry distribution chart, Harrow ranks #143 out of 1025 companies for Moat Score. This places Harrow in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Harrow's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (FRA:3IP) is currently considered Fairly Valued. The stock's GF Value™ is €33.34, compared to a current price of €33.00 — trading 1% below its estimated fair value. The current Moat Score is 3. Harrow's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Harrow (FRA:3IP), the current Moat Score is 3 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harrow (FRA:3IP) Overvalued in 2026?

Based on GuruFocus' analysis, Harrow stock appears to be undervalued. The current stock price of €33.00 is trading 1% below its estimated GF Value™ of €33.34. GuruFocus considers Harrow to be Fairly Valued.

Key valuation signals for FRA:3IP:

  • Moat Score: 3
  • GF Value™: €33.34 vs. price of €33.00 (1% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the FRA:3IP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harrow Business Description

Other Exchanges HROW:USA
Address 1A Burton Hills Boulevard, Suite 200, Nashville, TN, USA, 37215
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
76GF Score

Get the complete analysis for FRA:3IP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.00
Price
€33.34
GF Value